Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The mammalian ribosome is a complex macromolecular machine responsible for translating messenger RNA (mRNA) into proteins, a fundamental process for cellular survival, growth, and proliferation. Structurally, it is an 80S ribonucleoprotein complex composed of a small 40S subunit and a large 60S subunit, which together contain four ribosomal RNA (rRNA) molecules and approximately 80 ribosomal proteins. In oncology, the mammalian ribosome is a validated therapeutic target because rapidly proliferating cancer cells are highly dependent on elevated rates of protein synthesis to sustain their growth and biomass. Drugs like omacetaxine mepesuccinate (homoharringtonine) bind to the A-site cleft of the large ribosomal subunit, preventing the elongation step of translation and selectively inducing apoptosis in malignant cells, such as those in chronic myeloid leukemia (CML). Additionally, the ribosome can be targeted by translation readthrough-inducing drugs like ataluren, which interact with the decoding and peptidyl transferase centers to promote the suppression of premature stop codons, offering a therapeutic approach for genetic diseases caused by nonsense mutations.
Inhibition of protein translation elongation by binding to the ribosomal A-site cleft and preventing the correct positioning of incoming aminoacyl-tRNAs (e.g., omacetaxine mepesuccinate); or suppression of nonsense mutations by promoting the readthrough of premature stop codons through interaction with the decoding center and peptidyl transferase center (e.g., ataluren).
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mammalian ribosome (80S ribosome).